|
1
|
Crocetti E, Trama A, Stiller C, Caldarella
A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J and
Brandes A; RARECARE working group, : Epidemiology of glial and
non-glial brain tumours in Europe. Eur J Cancer. 48:1532–1542.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chhabda S, Carney O, D'Arco F, Jacques TS
and Mankad K: The 2016 world health organization classification of
tumours of the central nervous system: What the paediatric
neuroradiologist needs to know. Quant Imaging Med Surg. 6:486–489.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mittal S, Pradhan S and Srivastava T:
Recent advances in targeted therapy for glioblastoma. Expert Rev
Neurother. 15:935–946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Banelli B, Forlani A, Allemanni G,
Morabito A, Pistillo MP and Romani M: MicroRNA in glioblastoma: An
overview. Int J Genomics. 2017:76390842017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, He B, Xu T, Pan Y, Hu X, Chen X and
Wang S: MiR-490-3p functions as a tumor suppressor by inhibiting
oncogene VDAC1 expression in colorectal cancer. J Cancer.
9:1218–1230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian J, Xu YY, Li L and Hao Q: MiR-490-3p
sensitizes ovarian cancer cells to cisplatin by directly targeting
ABCC2. Am J Transl Res. 9:1127–1138. 2017.PubMed/NCBI
|
|
12
|
Tang B, Liu C, Zhang QM and Ni M:
Decreased expression of miR-490-3p in osteosarcoma and its clinical
significance. Eur Rev Med Pharmacol Sci. 21:246–251.
2017.PubMed/NCBI
|
|
13
|
Liu W, Xu G, Liu H and Li T:
MicroRNA-490-3p regulates cell proliferation and apoptosis by
targeting HMGA2 in osteosarcoma. FEBS Lett. 589:3148–3153. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hammond SM and Sharpless NE: HMGA2,
microRNAs and stem cell aging. Cell. 135:1013–1016. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sarhadi VK, Wikman H, Salmenkivi K, Kuosma
E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S:
Increased expression of high mobility group A proteins in lung
cancer. J Pathol. 209:206–212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu B, Pang B, Hou X, Fan H, Liang N,
Zheng S, Feng B, Liu W, Guo H, Xu S and Pang Q: Expression of high
mobility group AT-hook protein 2 and its prognostic significance in
malignant gliomas. Hum Pathol. 45:1752–1758. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu L, Du B, Lu QJ, Fan XW, Tang K, Yang L
and Liao WL: miR-541 suppresses proliferation and invasion of
squamous cell lung carcinoma cell lines via directly targeting
high-mobility group AT-hook 2. Cancer Med. 7:2581–2591. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao H, Zhao H, Xia X and Liu X:
MicroRNA-599 targets high-mobility group AT-hook 2 to inhibit cell
proliferation and invasion in clear cell renal carcinoma. Mol Med
Rep. 17:7451–7459. 2018.PubMed/NCBI
|
|
19
|
Komori T: The 2016 WHO classification of
tumours of the central nervous system: The major points of
revision. Neurol Med Chir (Tokyo). 57:301–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karnofsky DA and Burchenal JH: Evaluation
of chemotherapeutic agents. In: The Clinical Evaluation of
Chemotherapeutic Agents in Cancer. MacLeod CM (ed). Columbia
University Press; New York, NY: pp. 191–205. 1949
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang D, Liu Z, Zheng N, Wu H, Zhang Z and
Xu J: MiR-30b-5p modulates glioma cell proliferation by direct
targeting MTDH. Saudi J Biol Sci. 25:947–952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding CQ, Deng WS, Yin XF and Ding XD:
MiR-122 inhibits cell proliferation and induces apoptosis by
targeting runt-related transcription factors 2 in human glioma. Eur
Rev Med Pharmacol Sci. 22:4925–4933. 2018.PubMed/NCBI
|
|
26
|
Chiou SH, Dorsch M, Kusch E, Naranjo S,
Kozak MM, Koong AC, Winslow MM and Grüner BM: Hmga2 is dispensable
for pancreatic cancer development, metastasis, and therapy
resistance. Sci Rep. 8:140082018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hawsawi O, Henderson V, Burton LJ, Dougan
J, Nagappan P and Odero-Marah V: High mobility group A2 (HMGA2)
promotes EMT via MAPK pathway in prostate cancer. Biochem Biophys
Res Commun. 504:196–202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaur H, Ali SZ, Huey L, Hütt-Cabezas M,
Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG and
Raabe EH: The transcriptional modulator HMGA2 promotes stemness and
tumorigenicity in glioblastoma. Cancer Lett. 377:55–64. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Zhang X, Chen D and Ma C: Let-7a
suppresses glioma cell proliferation and invasion through
TGF-β/Smad3 signaling pathway by targeting HMGA2. Tumour Biol.
37:8107–8119. 2016. View Article : Google Scholar : PubMed/NCBI
|
